This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Leukaemia
  • /
  • Gemtuzumab ozogamicin for acute myeloid leukemia

Gemtuzumab ozogamicin for acute myeloid leukemia

Read time: 1 mins
Published:30th Nov 2017
Author: Appelbaum FR, Bernstein ID.
Source: Blood
Availability: Free full text
Ref.:Blood. 2017;130(22):2373-2376.

On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ acute myeloid leukemia and for patients aged ≥2 years with CD33+ acute myeloid leukemia who have experienced a relapse or who have not responded to initial treatment. This signals a new chapter in the long and unusual story of GO, which was the first antibody-drug conjugate approved for human use by the FDA.


Read abstract on library site

Access full article